[
1. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018 Jan;50(1):74-87.10.1016/j.pathol.2017.09.00629167021
]Search in Google Scholar
[
2. Gascoyne DR. The biology of diffuse large b-cell lymphoma (DLBCL). Pathology. 2014;46(suppl 1):S32.10.1097/01.PAT.0000443472.82045.44
]Search in Google Scholar
[
3. Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018 May 24;131(21):2307-19.10.1182/blood-2017-11-764332596937429666115
]Search in Google Scholar
[
4. Chiapella A, Vitolo U. Diffuse large b-cell lymphoma. In:Ghielmini M, Montoto S, editors. ESMO. Lymphomas Essential for Clinicians. Second edition Viganello-Lugano. 2015:31-7.
]Search in Google Scholar
[
5. Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, et al. Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Med Wkly. 2012 January 30;142:w13511.10.4414/smw.2012.1351122290632
]Search in Google Scholar
[
6. Nowakowski GS, Czuczman MS. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection? Am SocClinOncolEduc Book. 2015:e449-57.10.14694/EdBook_AM.2015.35.e44925993209
]Search in Google Scholar
[
7. Dunleavy K, Wilson WH. Appropriate management of molecular subtypes of diffuse large B-cell lymphoma. Oncology (Williston Park). 2014;28(4):326-34.
]Search in Google Scholar
[
8. Quintanilla-Martinez L. The 2016 updated WHO classification of lymphoid neoplasias. HematolOncol. 2017 Jun;35Suppl 1:37-45.10.1002/hon.239928591427
]Search in Google Scholar
[
9. Genova M, Balatzenko G. Cellular origin of diffuse large B-cell lymphoma. In: Predictive Biomarkers.
]Search in Google Scholar
[
10. Bolen CR, Klanova M, Trneny M, Sehn LH, He J, Tong J, et al. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica. 2020 Sep 1;105(9):2298-307.10.3324/haematol.2019.227892755663033054054
]Search in Google Scholar
[
11. Miao Y, Medeiros J, Li J, Young HK. Diffuse large B-cell lymphoma with molecular variations more than ABC and GCB classification. Precision Cancer Medicine. 2018:1-4.10.21037/pcm.2018.06.03
]Search in Google Scholar
[
12. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J ClinOncol. 2006 Feb 20;24(6):961-8.10.1200/JCO.2005.03.426416418494
]Search in Google Scholar
[
13. Riedell PA, Smith SM. Double hit and double expressors in lymphoma: Definition and treatment. Cancer (2018) 124: 4622-32.10.1002/cncr.3164630252929
]Search in Google Scholar
[
14. Li S, Wang Z, Lin L, Wu Z, Yu Q, Gao F, Zhang J, Xu Y. BCL6 Rearrangement Indicates Poor Prognosis in Diffuse Large B-cell Lymphoma Patients: A Meta-analysis of Cohort Studies. J Cancer 2019;10(2):530-8.10.7150/jca.25732636030630719149
]Search in Google Scholar
[
15. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM. Double-hit B-cell lymphomas. Blood. 2011 Feb 24;117(8):2319-31.10.1182/blood-2010-09-29787921119107
]Search in Google Scholar
[
16. Chiappella A, Crombie J, Guidetti A, Vitolo U, Armand P, Corradini P. Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? Hemasphere. 2019 July 31;3(5):e284.10.1097/HS9.0000000000000284691946331942539
]Search in Google Scholar
[
17. Aggarwal A, Rafei H, Alakeel F, Finianos N A, Liu LM, El-Bahesh E et al. Outcome of Patients with Double-Expressor Lymphomas (DELs) Treated with R-CHOP or R-EPOCH. Blood 2016;128(22):5396.10.1182/blood.V128.22.5396.5396
]Search in Google Scholar
[
18. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021 Mar 4;384(9):842-58.10.1056/NEJMra2027612837761133657296
]Search in Google Scholar
[
19. Swerdlow H S, Campo E, Pileri A S, Harris L N, Stein H, Siebert R et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375–90.10.1182/blood-2016-01-643569487422026980727
]Search in Google Scholar
[
20. Hans P Ch, Weisenburger D D, Greiner C T, Gascoyne D R, Delabie J, Ott G. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103(1):275–82.10.1182/blood-2003-05-154514504078
]Search in Google Scholar
[
21. Kumar V, Shrivastava MS, Meghal T, Chandra A B. Recent Advances in Diffuse Large B Cell Lymphoma. DOI: 10.5772/intechopen.74263.10.5772/intechopen.74263
]Search in Google Scholar
[
22. Sehn H L, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109(5):1857–61.10.1182/blood-2006-08-03825717105812
]Search in Google Scholar
[
23. Zhong Q, Shi Y. Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma. Front Oncol. 2021 January 14;10:582567.10.3389/fonc.2020.582567784134933520698
]Search in Google Scholar
[
24. Davies A, Cummin E T, Barrans R, Maishman T, Mamot C, Novak U et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B):an open-lable, randomized, phase 3 trial. The Lancet oncology. 2019;(20):649-62.10.1016/S1470-2045(18)30935-5
]Search in Google Scholar
[
25. Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Adv Ther. 2017;34(2):324-56.10.1007/s12325-016-0451-1533108828004361
]Search in Google Scholar
[
26. Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3529-37.10.1200/JCO.2017.73.340228796588
]Search in Google Scholar
[
27. Sehn LH, Martelli M, Trněný M, Liu W, Bolen CR, Knapp A, Sahin D, Sellam G, Vitolo U. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020 June 06;13(1):71.10.1186/s13045-020-00900-7727608032505213
]Search in Google Scholar
[
28. Zelenetz D A, Salles G, Mason D K, Casulo C, Gouill L S, Sehn H L et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood 2019; 133 (18): 1964–1976.10.1182/blood-2018-11-880526649751730850381
]Search in Google Scholar
[
29. Roberts A, Huang D. Targeting BCL2 with BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. Clin. Pharmacol. Ther.2017;101:89-98.
]Search in Google Scholar
[
30. Morschhauser M, Feugier P, Flinn W I, Gasiorowski E R, Greil R, Illés A et al. Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study. Blood 2018;132 (Suppl 1):782.10.1182/blood-2018-99-118519
]Search in Google Scholar
[
31. Vitolo U, Novo M; Bcl-2 inhibition in DLBCL: “the times they are a-changing”? Blood 2021;137 (5):577–9.10.1182/blood.202000892433538802
]Search in Google Scholar
[
32. Vitolo U, Witzig T, Gascoyne R, Scott D, Zhang Q, Jurczak W. et al., ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol. 2019;37:36-7.10.1002/hon.5_2629
]Search in Google Scholar
[
33. Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021 Apr 20;39(12):1317-28.10.1200/JCO.20.01366807832533621109
]Search in Google Scholar
[
34. Pasqualucci L, Zhang B. Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma. Semin Cancer Biol. 2016 Aug;39:26-31.10.1016/j.semcancer.2016.08.00127546290
]Search in Google Scholar
[
35. Davis E R, Brown D K, Siebenlist U, Staudt M L. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells. J Exp Med December 17 2001;194 (12):1861–74.10.1084/jem.194.12.1861219358211748286
]Search in Google Scholar
[
36. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011 Mar;11(3):239-53.10.2174/156800911794519752330661121247388
]Search in Google Scholar
[
37. Accardi F, Toscani D, Bolzoni M, Palma D B, Aversa F, Giuliani N. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling BioMed Research International, vol. 2015, Article ID 172458, 13 pages, 2015.
]Search in Google Scholar
[
38. Davies A. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?. Hematology Am Soc Hematol Educ Program 2017. 2017;1:284–94.10.1182/asheducation-2017.1.284614253829222268
]Search in Google Scholar
[
39. Goranov S, Goranova-MarinovaV. Chronic lymphocytic leukemia- new drugs replace the current standard. Hematology. 2019;1-2:13-21.
]Search in Google Scholar
[
40. Castillo JJ, Treon SP, Davids MS. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb;22(1):34-9.10.1097/PPO.000000000000017026841015
]Search in Google Scholar
[
41. Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppä S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Dührsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019 May 20;37(15):1285-95.10.1200/JCO.18.02403655383530901302
]Search in Google Scholar
[
42. Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illés Á, Johnson NA, Larouche JF, Lugtenburg PJ, Patti C, Salles GA, Trněný M, de Vos S, Mir F, Samineni D, Kim SY, Jiang Y, Punnoose E, Sinha A, Clark E, Spielewoy N, Humphrey K, Bazeos A, Zelenetz AD. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021 Feb 4;137(5):600-9.10.1182/blood.2020006578786918633538797
]Search in Google Scholar
